AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LTR PHARMA LTD

0.505

+0.0357.45%

Volume:404.27K

Turnover:202.19K

Market Cap:91.73M

PE:-10.10

High:0.510

Open:0.490

Low:0.490

Close:0.470

52wk High:0.810

52wk Low:0.350

Shares:181.65M

Float Shares:100.83M

Volume Ratio:4.78

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.078

ROE:-54.73%

ROA:-30.85%

PB:4.53

PE(LYR):-6.47

Loading ...

Overview Company News Filings

LTR Pharma Ltd - Statutory Loss After Tax for FY26 A$14.2 Million

THOMSON REUTERS

ASX Penny Stocks To Watch In August 2026

Simply Wall St.

LTR Pharma Reports Real-World Findings for Intranasal Erectile Dysfunction Spray; Shares Jump 12%

MT Newswires Live

LTR Pharma - Agreement Establishes Manufacturing and Supply-chain Framework for Roxus U.S. Launch

THOMSON REUTERS

LTR Pharma Ltd-ltr Executes U.S. Commercial Agreement with Strive

THOMSON REUTERS

Australia's LTR Pharma Rises on Commercial Tie-up with US Telehealth Firm

LTR Pharma Executes Definitive US Distribution Agreement With Shed Holdings for ROXUS, Shares Up 11%

MT Newswires Live

LTR Pharma Ltd-ltr Executes Definitive U.S. Commercial Agreement with Shed

THOMSON REUTERS

LTR Pharma - Establishes Framework for U.S. Roxus Commercialisation Via Shed's Mavrox Platform

THOMSON REUTERS

BUZZ-Australia's LT Pharma gains after nod to test nasal spray

BRIEF-LTR Pharma Says Oroflow Becomes First GI Application Of Intranasal Platform

LTR Pharma Gets Ethics Committee Approval for Trial of Intranasal Spray in Patients With Oesophageal Motility Disorders

MT Newswires Live

LTR Pharma - Oroflow Becomes First Gi Application of LTR Pharma Intranasal Platform in Clinical Evaluation

THOMSON REUTERS

BUZZ-Australia's LTR Pharma gains on US deal for Roxus

LTR Pharma Establishes Exclusive US Pharmacy Fulfilment Rights for Erectile Dysfunction Product, Shares Jump 22%

MT Newswires Live

LTR Pharma Ltd-Ltr Secures Exclusive U.S. Pharmacy Partner for Roxus

THOMSON REUTERS

BUZZ-Australia's LTR Pharma hits over a month high on US distribution deal

LTR Pharma Ltd-Ltr Secures First U.S. Commercial Agreement for Roxus

THOMSON REUTERS

ASX Penny Stocks With Market Caps Under A$200M To Watch

Simply Wall St.

SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/LTP.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LTP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"LTP.AU\",,,,,undefined,":{"symbol":"LTP.AU","market":"AU","secType":"STK","nameCN":"LTR PHARMA LTD","latestPrice":0.505,"timestamp":1788156720000,"preClose":0.47,"halted":0,"volume":404271,"delay":0,"changeRate":0.07446808510638304,"nameEN":"LTR PHARMA LTD","floatShares":100829062,"shares":181645077,"eps":-0.05,"marketStatus":"Not Yet Opened","change":0.035,"latestTime":"08-31 16:12:00 AEST","open":0.49,"high":0.51,"low":0.49,"amount":202192,"amplitude":0.042553,"askPrice":0.515,"askSize":34000,"bidPrice":0.495,"bidSize":4400,"shortable":3,"etf":0,"ttmEps":-0.05,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"listingDate":1702126800000,"exchange":"ASX","adjPreClose":0.47,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":4.775343147617635,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"LTP.AU","preClose":0.47,"auctionPrice":0.49,"auctionVolume":30160,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156003058}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"LTP.AU\",,,,,undefined,":{"symbol":"LTP.AU","floatShares":100829062,"roa":"-30.85%","roe":"-54.73%","lyrEps":-0.078,"volumeRatio":4.775343147617635,"shares":181645077,"dividePrice":0,"high":0.51,"amplitude":0.042553,"preClose":0.47,"low":0.49,"week52Low":0.35,"pbRate":"4.53","psRate":"56.61","week52High":0.81,"institutionHeld":0,"latestPrice":0.505,"committee":-0.770833,"eps":-0.05,"divideRate":0,"volume":404271,"delay":0,"ttmEps":-0.05,"open":0.49,"prevYearClose":0.72,"prevWeekClose":0.47,"prevMonthClose":0.505,"prevQuarterClose":0.545,"fiveDayClose":0.5,"twentyDayClose":0.46,"sixtyDayClose":0.465},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LTP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LTP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LTP.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662341036","title":"LTR Pharma Ltd - Statutory Loss After Tax for FY26 A$14.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662341036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662341036?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867421,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1JV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659049190","title":"ASX Penny Stocks To Watch In August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659049190","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659049190?lang=en_us&edition=fundamental","pubTime":"2026-08-14 10:04","pubTimestamp":1786673084,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing some fluctuations, with the S&P/ASX 200 recently dipping by 0.23%, while Wall Street continues to show strength with record highs. In this context, penny stocks remain a compelling area of interest for investors seeking opportunities in smaller or less-established companies. Despite their vintage name, these stocks can offer significant value when they possess strong financials and growth potential, making them worth considering for those looking to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ltp/ltr-pharma-shares/news/asx-penny-stocks-to-watch-in-august-2026-4","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ltp/ltr-pharma-shares/news/asx-penny-stocks-to-watch-in-august-2026-4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","RIM.AU","LTP.AU","BK7096","DLI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969529","title":"LTR Pharma Reports Real-World Findings for Intranasal Erectile Dysfunction Spray; Shares Jump 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969529","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658969529?lang=en_us&edition=fundamental","pubTime":"2026-08-11 11:40","pubTimestamp":1786419651,"startTime":"0","endTime":"0","summary":"LTR Pharma  said real-world findings for its intranasal spray product for erectile dysfunction from a group of 147 participants support the product's efficacy, according to a Tuesday Australian bourse filing.Outcomes were assessed using a patient-reported composite measure of improved erectile hardness and/or achieving penetration following treatment, the company said. The company added that 68%, or 100 of the total group of 147 participants, with a mean age of 65.6 years, all of whom had previously been treated with oral PDE5 inhibitors, reported improved erectile hardness and/or achieving penetration with the product.Moreover, 62% of the group had a history of prostate cancer, and 59% had undergone prostatectomy, per the filing. Meanwhile, 64% of post-prostatectomy patients, or 56 of 87 participants, reported improved erectile hardness and/or achieving penetration with the product.LTR Pharma's shares jumped nearly 12% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652683132","title":"LTR Pharma - Agreement Establishes Manufacturing and Supply-chain Framework for Roxus U.S. Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2652683132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652683132?lang=en_us&edition=fundamental","pubTime":"2026-07-20 06:55","pubTimestamp":1784501758,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nTUE1SHQ8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652268392","title":"LTR Pharma Ltd-ltr Executes U.S. Commercial Agreement with Strive","url":"https://stock-news.laohu8.com/highlight/detail?id=2652268392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652268392?lang=en_us&edition=fundamental","pubTime":"2026-07-20 06:55","pubTimestamp":1784501758,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nTUE1SHQ8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652476991","title":"Australia's LTR Pharma Rises on Commercial Tie-up with US Telehealth Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2652476991","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652476991?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:06","pubTimestamp":1784253998,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's LTR Pharma rises on commercial tie-up with US telehealth firm** Shares of Australia's LTR PharmaLTP.AXrise as much as 17.2% to A$0.58, their biggest intraday pct gain since June 18** Stock at its highest level since July 3** LTP set to clock its second consecutive session of gains, if trend holds** Stock up 1.9% in the week so far** The clinical-stage biopharma firmsignsa commercial agreement executed with Shed, a U.S. direct-to-consumer  telehealth platform** Near 547,114 shares change hands, 1.0x the 30-day average volume** Stock has fallen 27.1% this year, including session moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nL4N43J05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652315476","title":"LTR Pharma Executes Definitive US Distribution Agreement With Shed Holdings for ROXUS, Shares Up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652315476","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652315476?lang=en_us&edition=fundamental","pubTime":"2026-07-17 09:56","pubTimestamp":1784253395,"startTime":"0","endTime":"0","summary":"LTR Pharma  executed a definitive telehealth distribution agreement with Shed Holdings, a US direct-to-consumer telehealth platform, converting a previously disclosed binding term sheet into a definitive commercial agreement for the planned US commercialization of ROXUS, according to a Friday Australian bourse filing.The company said Shed has committed to support the delivery of not less than 150,000 ROXUS units during the first 12 months following commercial launch.ROXUS is the company's fast-acting intranasal spray for the treatment of erectile dysfunction.The company's shares rose 11% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652427420","title":"LTR Pharma Ltd-ltr Executes Definitive U.S. Commercial Agreement with Shed","url":"https://stock-news.laohu8.com/highlight/detail?id=2652427420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652427420?lang=en_us&edition=fundamental","pubTime":"2026-07-17 06:48","pubTimestamp":1784242099,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUE1RSL5R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652420478","title":"LTR Pharma - Establishes Framework for U.S. Roxus Commercialisation Via Shed's Mavrox Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2652420478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652420478?lang=en_us&edition=fundamental","pubTime":"2026-07-17 06:48","pubTimestamp":1784242099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUE1RSL5R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645099861","title":"BUZZ-Australia's LT Pharma gains after nod to test nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2645099861","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645099861?lang=en_us&edition=fundamental","pubTime":"2026-06-24 13:08","pubTimestamp":1782277696,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's LT Pharma gains after nod to test nasal spray** LT Pharma shares LTP.AX rise as much as 14.2% to A$0.645, their highest level since January 9** *Biopharmaceutical co says its novel nasal spray receives ethics approval to conduct study evaluating its effects in patients with Oesophageal Motility Disorders ** Marks co's entry into the gastrointestinal diseases market, where OMD treatments alone are expected to reach $8.1 billion by 2034** 1.3 million shares traded so far vs 30-day average of 532,000** Stock down over 11% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL4N42W0EA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645863121","title":"BRIEF-LTR Pharma Says Oroflow Becomes First GI Application Of Intranasal Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2645863121","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645863121?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:38","pubTimestamp":1782265082,"startTime":"0","endTime":"0","summary":"BRIEF-LTR Pharma Says Oroflow Becomes First GI Application Of Intranasal PlatformJune 24 (Reuters) - LTR Pharma Ltd LTP.AX:OROFLOW BECOMES FIRST GI APPLICATION OF LTR PHARMA INTRANASAL PLATFORM IN CLINICAL EVALUATIONFurther company coverage: LTP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42V0Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645857650","title":"LTR Pharma Gets Ethics Committee Approval for Trial of Intranasal Spray in Patients With Oesophageal Motility Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2645857650","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645857650?lang=en_us&edition=fundamental","pubTime":"2026-06-24 07:05","pubTimestamp":1782255934,"startTime":"0","endTime":"0","summary":"LTR Pharma  received ethics committee approval for a clinical study to evaluate its Oroflow intranasal spray in patients with oesophageal motility disorders, which impede the food swallowing function, according to a Wednesday filing with the Australian bourse.The company expects to initiate the study in the coming quarter to assess Oroflow's effect in healthy volunteers before progressing to patients with the disorders.\"As a non-invasive intranasal spray, Oroflow may be particularly suited to patients with swallowing difficulties, removing the need to take an oral tablet while offering a rapid route of administration,\" the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645129852","title":"LTR Pharma - Oroflow Becomes First Gi Application of LTR Pharma Intranasal Platform in Clinical Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2645129852","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645129852?lang=en_us&edition=fundamental","pubTime":"2026-06-24 06:22","pubTimestamp":1782253349,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642056524","title":"BUZZ-Australia's LTR Pharma gains on US deal for Roxus","url":"https://stock-news.laohu8.com/highlight/detail?id=2642056524","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642056524?lang=en_us&edition=fundamental","pubTime":"2026-06-11 12:20","pubTimestamp":1781151618,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's LTR Pharma gains on US deal for Roxus** Shares of Australia's LTR Pharma LTP.AX rise as much as 25.9% to A$0.535, their biggest gain since June 5** The clinical-stage biopharma firm e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL6N42J09F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642408901","title":"LTR Pharma Establishes Exclusive US Pharmacy Fulfilment Rights for Erectile Dysfunction Product, Shares Jump 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642408901","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642408901?lang=en_us&edition=fundamental","pubTime":"2026-06-11 10:40","pubTimestamp":1781145651,"startTime":"0","endTime":"0","summary":"LTR Pharma  executed a binding term sheet with Strive Specialties, establishing exclusive US pharmacy fulfilment rights for its intranasal erectile dysfunction treatment product ROXUS, according to a Thursday Australian bourse filing.The term sheet provides access to a multi-state 503A pharmacy platform to support national pharmacy fulfilment.The agreement has a two-year initial term from commercial launch, with annual autorenewal unless either party elects not to renew. The product will be supplied through a multi-channel strategy incorporating telehealth, pharmacy fulfilment, and healthcare provider networks.Its shares soared 22% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642471470","title":"LTR Pharma Ltd-Ltr Secures Exclusive U.S. Pharmacy Partner for Roxus","url":"https://stock-news.laohu8.com/highlight/detail?id=2642471470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642471470?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:39","pubTimestamp":1781131142,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUE6FZHGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642456602","title":"BUZZ-Australia's LTR Pharma hits over a month high on US distribution deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2642456602","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642456602?lang=en_us&edition=fundamental","pubTime":"2026-06-09 11:02","pubTimestamp":1780974139,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's LTR Pharma hits over a month high on US distribution deal** Shares of Australia's LTR Pharma LTP.AX rise as much as 16.1% to A$0.54, its highest level since May 1** Stock on track for a third consecutive session of gains if the current trend holds** The clinical-stage biopharma co says it signs binding agreement with US-based direct-to-consumer  telehealth platform, Shed Holdings, to distribute ROXUS in the US** ROXUS is the company's oral drug treatment for erectile dysfunction** Despite moves, stock down 34.7% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nL6N42H06A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642437873","title":"LTR Pharma Ltd-Ltr Secures First U.S. Commercial Agreement for Roxus","url":"https://stock-news.laohu8.com/highlight/detail?id=2642437873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642437873?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:35","pubTimestamp":1780958156,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUE5JMKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641179927","title":"ASX Penny Stocks With Market Caps Under A$200M To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2641179927","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641179927?lang=en_us&edition=fundamental","pubTime":"2026-06-08 03:02","pubTimestamp":1780858971,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the Australian market has dropped 1.2%, remaining relatively flat over the past year, with earnings forecasted to grow by 12% annually. Investing in penny stocks—typically smaller or newer companies—can still open doors to growth opportunities when these stocks are backed by strong financial health. This article will explore several penny stocks that stand out as hidden gems, offering potential for impressive returns amidst current market conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ltp/ltr-pharma-shares/news/asx-penny-stocks-with-market-caps-under-a200m-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ltp/ltr-pharma-shares/news/asx-penny-stocks-with-market-caps-under-a200m-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUE.AU","VAP.AU","QFN.AU","XJO.AU","IOZ.AU","QRE.AU","OZF.AU","BK7111","BK7096","OZR.AU","BBOZ.AU","DACE.AU","GIVE.AU","XAO.AU","VAS.AU","IISV.AU","GEAR.AU","E200.AU","BIO.AU","LTP.AU","EIGA.AU","BK7142","IMLC.AU","STW.AU","ZYAU.AU","SLF.AU","XKO.AU","IIGF.AU","BEAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632335539","title":"SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2632335539","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632335539?lang=en_us&edition=fundamental","pubTime":"2026-05-04 14:00","pubTimestamp":1777874400,"startTime":"0","endTime":"0","summary":"Median Tmax of 10 minutes for SPONTAN  versus 60 minutes for oral vardenafil , consistent with Phase I study.Interim data provide the key pharmacokinetic dataset requested by the FDA, including rapid absorption, repeat-dose profile, with no drug accumulation observed, and consistent pharmacokinetics across adult and geriatric populations.Pharmacokinetic profile in subjects ≥65 years comparable to adults in the dataset, addressing a key FDA Pre-IND requirement.Consistent safety profile observed, with no serious adverse events, no Grade 3 or 4 treatment-emergent adverse events, and no treatment-related discontinuations.Interim data are expected to inform the Company's planned FDA 505 regulatory pathway.SPONTAN Phase II study design. Randomised, three-way crossover  followed by multiple-dose evaluation .The interim results indicate that the Study has characterised the key pharmacokinetic parameters requested by the FDA, including rapid absorption, repeat-dose behaviour, and consistency ac","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2971713/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2971713/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/spontan-phase-ii-interim-data-demonstrates-rapid-onset-and-pharmacokinetic-profile-addressing-fda-pre-ind-requirements-across-adult-and-65-populations-302761066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4218","LTP.AU","IND","PK","BK4585","BK7096","BK4181"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}